0001171843-26-000859
SEC filingBeta Bionics, Inc. reported Q4 2025 net sales of $32.1 million, up 57% year-over-year, and full year 2025 net sales of $100.3 million, up 54%, with gross margins of 59.0% and 55.4%, respectively, and introduced 2026 guidance of $130-135 million in revenue. The company ended 2025 with $264.7 million in cash and highlighted progress in its bihormonal system development.